AI-guided diagnostics are rapidly transforming clinical detection for high-risk individuals.
Freenome’s novel AI-powered blood diagnostic test designed to detect early-stage lung cancer has successfully secured the coveted “Breakthrough Device” designation from the FDA. Aimed primarily at high-risk adults who struggle to follow standard imaging-based screening protocols, this intelligent liquid biopsy tool utilizes sophisticated foundation models to intercept cancer signals earlier. The milestone arrives just as the federal government prepares to tighten alternative Medicare reimbursement pathways for medical technologies.
About the Author
